A Phase 1/2 Study of EP0031, Alone and With Standard Chemotherapy, in People With Solid Tumors

Full Title

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies

Purpose

Researchers want to see how well EP0031 works when given alone or with standard chemotherapy to treat cancer. The people in this study have solid tumors with a mutation (change) in a gene called RET.

EP0031 blocks the RET protein, which plays a role in cancer growth. By blocking RET, EP0031 may help slow or stop the growth of your cancer.

If you join this study, you will take EP0031 alone or in combination with chemotherapy drugs such as pemetrexed, carboplatin, or cisplatin. EP0031 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a solid tumor that has a RET mutation.
• Have recovered from the serious side effects of prior anti-cancer therapies before getting the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Alexander Drilon’s office at 646-608-3758.